A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

May 31, 2016

Conditions
Heart FailureDilated Cardiomyopathy
Interventions
DEVICE

Algisyl-LVR

Algisyl-LVR™ device (implants) administered during a surgical procedure

DRUG

Standard medical therapy

as defined per protocol

Trial Locations (18)

1024

Auckland City Hospital, Auckland

3004

Heart Center at the Alfred, Melbourne

20097

IRCCS Policlinico San Donato, San Donato

20132

Istituto Scientifico Universitario San Raffaele, Milan

24128

Ospedali riuniti Dipartimento Cardiovascolare, Bergamo

35128

Azienda Ospedaliera di Padova, Padua

Unknown

Charité (Campus Virchov), Berlin

Charité - Universitätsmedizin Berlin (Campus Benjamin Franklin), Berlin

Herzzentrum Dresden Universitätsklinik, Dresden

Universität Schleswig-Holstein Campus Kiel, Kiel

Universitätsklinikum Ulm, Ulm

Istituti Ospitalieri di Cremona, Cremona

Centrului Clinic de Urgenta de Boli Cardiovasculare al Armatei, Bucharest

"Clinica de Cardiologie, Spitalul Clinic de Urgenta Sf. Pantelimon", Bucharest

"Spitalul Clinic De Urgenta MAI Prof. Dr. Dimitrie Gerota", Bucharest

00163

IRCCS San Raffaele Roma, Rome

00161

Policlinico Umberto I, Rome

3435 CM

St. Antonius Ziekenhuis Nieuwegein, Nieuwegein

All Listed Sponsors
lead

LoneStar Heart, Inc.

INDUSTRY

NCT01311791 - A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure | Biotech Hunter | Biotech Hunter